Literature DB >> 23846683

Synthetic dimeric Aβ(28-40) mimics the complex epitope of human anti-Aβ autoantibodies against toxic Aβ oligomers.

Andreas M Roeder1, Yvonne Roettger2, Anne Stündel2, Richard Dodel3, Armin Geyer4.   

Abstract

Covalently linked carboxyl-terminal segments of the β-amyloid peptide (Aβ) were tested for their qualification as minimal conformational epitopes of the naturally occurring human autoantibodies against β-amyloid (nAbs-Aβ). nAbs-Aβ specifically recognize the toxic oligomers of Aβ and not the monomeric or the fibrillar forms of Aβ. The synthetic dimers of Aβ(28-40) described herein mimic the toxic Aβ oligomers but are not kinetic intermediates with uncertain compositions. CD spectra identified a surprisingly rich conformational behavior of selected miniamyloids. We observed a highly cooperative conformational transition of β-sheet to α-helix upon the addition of the helix enforcing co-solvent hexafluoroisopropanol. The CD curves of dimer 9 resembled, in a completely reversible manner, the CD spectra measured during the irreversible fibrillation of the parent Aβ(1-40). Synthetic peptide epitopes with high affinities for nAbs-Aβ are needed to identify the physiological roles of nAbs-Aβ and are promising epitopes for vaccination experiments.

Entities:  

Keywords:  Alzheimer Disease; Amyloid; Autoantibodies; Neuroimmunology; Neurological Diseases; Peptide Chemical Synthesis; Peptide Conformation; Protein Aggregation

Mesh:

Substances:

Year:  2013        PMID: 23846683      PMCID: PMC3779759          DOI: 10.1074/jbc.M113.463273

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

2.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

3.  Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease.

Authors:  R C Dodel; Y Du; C Depboylu; H Hampel; L Frölich; A Haag; U Hemmeter; S Paulsen; S J Teipel; S Brettschneider; A Spottke; C Nölker; H J Möller; X Wei; M Farlow; N Sommer; W H Oertel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

4.  Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.

Authors:  Ming Jin; Nina Shepardson; Ting Yang; Gang Chen; Dominic Walsh; Dennis J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-18       Impact factor: 11.205

5.  3D structure of Alzheimer's amyloid-beta(1-42) fibrils.

Authors:  Thorsten Lührs; Christiane Ritter; Marc Adrian; Dominique Riek-Loher; Bernd Bohrmann; Heinz Döbeli; David Schubert; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-17       Impact factor: 11.205

6.  Solid-phase synthesis of homodimeric peptides: preparation of covalently-linked dimers of amyloid beta peptide.

Authors:  W Mei Kok; Denis B Scanlon; John A Karas; Luke A Miles; Deborah J Tew; Michael W Parker; Kevin J Barnham; Craig A Hutton
Journal:  Chem Commun (Camb)       Date:  2009-09-01       Impact factor: 6.222

7.  The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding.

Authors:  Simona Tomaselli; Veronica Esposito; Paolo Vangone; Nico A J van Nuland; Alexandre M J J Bonvin; Remo Guerrini; Teodorico Tancredi; Piero A Temussi; Delia Picone
Journal:  Chembiochem       Date:  2006-02       Impact factor: 3.164

8.  A disulfide-linked amyloid-beta peptide dimer forms a protofibril-like oligomer through a distinct pathway from amyloid fibril formation.

Authors:  Takahiro Yamaguchi; Hisashi Yagi; Yuji Goto; Katsumi Matsuzaki; Masaru Hoshino
Journal:  Biochemistry       Date:  2010-08-24       Impact factor: 3.162

9.  Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity.

Authors:  Yansheng Du; Xing Wei; Richard Dodel; Norbert Sommer; Harald Hampel; Feng Gao; Zhizhong Ma; Liming Zhao; Wolfgang H Oertel; Martin Farlow
Journal:  Brain       Date:  2003-06-23       Impact factor: 13.501

10.  Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers.

Authors:  Rakez Kayed; Elizabeth Head; Floyd Sarsoza; Tommy Saing; Carl W Cotman; Mihaela Necula; Lawrence Margol; Jessica Wu; Leonid Breydo; Jennifer L Thompson; Suhail Rasool; Tatyana Gurlo; Peter Butler; Charles G Glabe
Journal:  Mol Neurodegener       Date:  2007-09-26       Impact factor: 14.195

View more
  4 in total

1.  Supersaturation-limited amyloid fibrillation of insulin revealed by ultrasonication.

Authors:  Hiroya Muta; Young-Ho Lee; József Kardos; Yuxi Lin; Hisashi Yagi; Yuji Goto
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

2.  Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein.

Authors:  Alexandra Albus; Maike Gold; Jan-Philipp Bach; Monika Burg-Roderfeld; Marit Jördens; Yvonne Kirchhein; Yannick Kronimus; David Mengel; Inga Zerr; Richard Dodel
Journal:  PLoS One       Date:  2018-08-29       Impact factor: 3.240

3.  Assembly of synthetic Aβ miniamyloids on polyol templates.

Authors:  Sebastian Nils Fischer; Armin Geyer
Journal:  Beilstein J Org Chem       Date:  2015-12-17       Impact factor: 2.883

4.  Encoding the Sequence of Specific Autoantibodies Against beta-Amyloid and alpha-Synuclein in Neurodegenerative Diseases.

Authors:  Alexandra Albus; Marit Jördens; Moritz Möller; Richard Dodel
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.